TY - JOUR
T1 - Insulin-like growth factor receptor inhibitors
T2 - Baby or the bathwater?
AU - Yee, Douglas
PY - 2012/7/3
Y1 - 2012/7/3
N2 - The success of targeted therapies for cancer is undisputed; strong preclinical evidence has resulted in the approval of several new agents for cancer treatment. The type I insulin-like growth factor receptor (IGF1R) appeared to be one of these promising new targets. Substantial population and preclinical data have all pointed toward this pathway as an important regulator of tumor cell biology. Although early results from clinical trials that targeted the IGF1R showed some evidence of response, larger randomized phase III trials have not shown clear clinical benefit of targeting this pathway in combination with conventional strategies. These disappointing results have resulted in the discontinuation of several anti-IGF1R programs. However, the conduct of these trials has brought to the forefront several important factors that need to be considered in the conduct of future clinical trials. The need to develop biomarkers, a clearer understanding of insulin receptor function, and defining rational combination regimens all require further consideration. In this commentary, the current state of IGF1R inhibitors in cancer therapy is reviewed.
AB - The success of targeted therapies for cancer is undisputed; strong preclinical evidence has resulted in the approval of several new agents for cancer treatment. The type I insulin-like growth factor receptor (IGF1R) appeared to be one of these promising new targets. Substantial population and preclinical data have all pointed toward this pathway as an important regulator of tumor cell biology. Although early results from clinical trials that targeted the IGF1R showed some evidence of response, larger randomized phase III trials have not shown clear clinical benefit of targeting this pathway in combination with conventional strategies. These disappointing results have resulted in the discontinuation of several anti-IGF1R programs. However, the conduct of these trials has brought to the forefront several important factors that need to be considered in the conduct of future clinical trials. The need to develop biomarkers, a clearer understanding of insulin receptor function, and defining rational combination regimens all require further consideration. In this commentary, the current state of IGF1R inhibitors in cancer therapy is reviewed.
UR - http://www.scopus.com/inward/record.url?scp=84863900275&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863900275&partnerID=8YFLogxK
U2 - 10.1093/jnci/djs258
DO - 10.1093/jnci/djs258
M3 - Review article
C2 - 22761272
AN - SCOPUS:84863900275
SN - 0027-8874
VL - 104
SP - 975
EP - 981
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 13
ER -